Literature DB >> 20550474

Predicting the no-reflow phenomenon following successful percutaneous coronary intervention.

L Galiuto1, L Paraggio, G Liuzzo, A R de Caterina, F Crea.   

Abstract

In the setting of acute myocardial infarction, early and adequate reopening of an infarct-related artery is not necessarily followed by a complete restoration of myocardial perfusion. This condition is usually defined as 'no-reflow'. The pathophysiology of no-reflow is multifactorial since extravascular compression, microvascular vasoconstriction, embolization during percutaneous coronary intervention, and platelet and neutrophil aggregates are involved. In the clinical arena, angiographic findings and easily available clinical parameters can predict the risk of no-reflow. More recently, several studies have demonstrated that biomarkers, especially those related to the pathogenetic components of no-reflow, could also have a prognostic role in the prediction and in the full understanding of the multiple mechanisms of this phenomenon. Thus, in this article, we investigate the role of several biomarkers on admission in predicting the occurrence of no-reflow following successful percutaneous coronary intervention.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20550474     DOI: 10.2217/bmm.10.55

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  2 in total

Review 1.  Use of contrast echocardiography in intensive care and at the emergency room.

Authors:  Bernard Cosyns; Bram Roossens; Sophie Hernot; Philippe El Haddad; Herve Lignian; Luc Pierard; Patrizio Lancellotti
Journal:  Curr Cardiol Rev       Date:  2011-08

2.  Patients with ST-segment elevation of myocardial infarction miss out on early reperfusion: when to undergo delayed revascularization.

Authors:  Wen Zheng; Cheuk-Man Yu; Jing Liu; Wu-Xiang Xie; Miao Wang; Yu-Jiao Zhang; Jian Sun; Shao-Ping Nie; Dong Zhao
Journal:  J Geriatr Cardiol       Date:  2017-08       Impact factor: 3.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.